diagnosed were Gleason score 6. In addition, there were 4 (24%) cases of ASAP and 4 (24%) cases of HGPIN diagnosed.
INTRODUCTION AND OBJECTIVES: Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed by prostate cancer (PCa) cells and can be targeted using the novel PET radiotracer 18 F-DCFPyL. This prospective trial aimed to determine the diagnostic performance of 18 F-DCFPyL PET/CT for detecting pelvic lymph node metastases and other distant sites of disease in men with PCa.
METHODS:
18 F-DCFPyL PET/CT was evaluated in 385 men with high-risk PCa planned for radical prostatectomy and lymphadenectomy (Cohort A, n[268) or radiological evidence of metastatic PCa feasible for biopsy (Cohort B, n[117) . 9 mCi (333 MBq) of 18 F-DCFPyL was administered 1-2 hours prior to PET/CT. The coprimary endpoints of sensitivity and specificity of 18 F-DCFPyL PET/CT for detecting pelvic lymph node metastases were evaluated in Cohort A. Secondary endpoints included safety in both cohorts, positive predictive value (PPV) and negative predictive value (NPV) in Cohort A, and sensitivity and PPV in Cohort B. Three central, blinded, and independent readers evaluated the 18 F-DCFPyL scans. Histopathology served as the reference standard to which imaging findings were compared.
RESULTS: In Cohort A (n[252 evaluable), the sensitivity of 18 F-DCFPyL PET/CT ranged among the three readers from 30.6-41.9% (lower bound of 95% CI: 19.2-29.7%), with a range of specificities of 96.3-98.9% (lower bound of 95% CI: 93.6-96.0%). Additionally, the PPV and NPV ranged from 78.1-90.5% and 81.4-83.8%, respectively. When the analysis was restricted to median lymph node metastases >4 mm, there was a marked improvement in sensitivity (range 50.0-66.7%; lower bound of 95% CI: 32.0-49.8%). In patients with distant metastatic PCa (Cohort B, n[93 evaluable), the values of sensitivity and PPV ranged from 92.9-98.6% (lower bound of 95% CI: 84.0-91.6%) and 81.2-87.8%, respectively. No drug-related serious adverse events were observed and 27 (7.0%) men experienced !1 drug-related adverse event, with dysgeusia (2.1%) and headache (2.1%) being most common.
CONCLUSIONS:
18 F-DCFPyL PET/CT was well tolerated and demonstrated high overall diagnostic performance in the detection of pelvic lymph node metastases and other distant sites of metastatic disease, as evidenced by its high specificity and PPV. These data suggest that 18 F-DCFPyL PET/CT could enable more accurately informed treatment choices in men with prostate cancer. ClinicalTrials.gov identifier NCT02981368. (1404) is a small molecule SPECT imaging agent that binds to prostatespecific membrane antigen (PSMA) allowing for the detection of prostate cancer (PCa). SPECT/CT is an imaging technique with advantages over PET/CT that include a ubiquitous, low cost option for PCa imaging. The objective of this trial was to evaluate the sensitivity and specificity of 1404 SPECT/CT to detect clinically significant PCa in men with low-grade PCa at initial biopsy who were candidates for active surveillance.
METHODS: This Phase 3 trial was a multi-center, multi-reader, open-label trial evaluating 1404 SPECT/CT imaging in men who had biopsy proven PCa with Gleason score (GS) 3þ4 within 12 months of enrollment and were candidates for active surveillance, planning to undergo follow-up biopsy or radical prostatectomy with or without a pelvic lymph node dissection. A single dose of 1404 (20 AE 3 mCi) was administered by intravenous injection followed by whole body planar and SPECT/CT (pelvic) imaging 3-6 hours later. 1404 images were reviewed by three independent, central imaging readers and evaluated for uptake consistent with clinically significant PCa. These findings were then compared against central histopathology as the truth standard. Clinically significant disease was defined as GS >3þ4 or 3þ4 with !10% pattern 4, and either any GS with !pT3 disease (radical prostatectomy) or GS 3þ3 with intraductal carcinoma of prostate (biopsy). The co-primary endpoints of specificity and sensitivity were calculated for correctly identifying subjects with clinically significant prostate cancer, requiring a lower limit of the two-sided 95% confidence intervals (CIs) to exceed 60%.
RESULTS: 1404 SPECT/CT was evaluated for its diagnostic performance in 465 men. The median PSA level for patients dosed in the trial was 5.58 ng/mL (range: 0.69-16.03). 1404 was very well tolerated. The most frequent adverse events included headache (2.3%), dizziness (1.1%), and fatigue (0.8%). 1404 SPECT/CT detected clinically significant PCa among the three readers with sensitivity of 47-51% (95% CI: 41-56%), specificity of 71-75% (95% CI: 64-80%), and PPV of 75-77% (95% CI: 68-83%).
CONCLUSIONS: 1404 SPECT/CT achieved the co-primary endpoint of specificity, successfully identifying patients without clinically significant PCa. However, the sensitivity endpoint did not achieve the pre-specified lower-bound. ClinicalTrials.gov: NCT02615067 
